414 related articles for article (PubMed ID: 31938902)
21. Castleman disease and TAFRO syndrome: To improve the diagnostic consciousness is the key.
Zhou QY
World J Clin Cases; 2022 Feb; 10(5):1536-1547. PubMed ID: 35211591
[TBL] [Abstract][Full Text] [Related]
22. Elevated serum interferon γ-induced protein 10 kDa is associated with TAFRO syndrome.
Iwaki N; Gion Y; Kondo E; Kawano M; Masunari T; Moro H; Nikkuni K; Takai K; Hagihara M; Hashimoto Y; Yokota K; Okamoto M; Nakao S; Yoshino T; Sato Y
Sci Rep; 2017 Feb; 7():42316. PubMed ID: 28205564
[TBL] [Abstract][Full Text] [Related]
23. [TAFRO syndrome and monoclonal gammapathy: Uncommon association!].
Naifar M; Messedi M; Elleuch A; Snoussi M; Gouiaa N; Turki M; Lahiani A; Boudawara T; Bahloul Z; Ayedi F
Curr Res Transl Med; 2016; 64(1):43-7. PubMed ID: 27140598
[TBL] [Abstract][Full Text] [Related]
24. TAFRO Syndrome: A Disease Requiring Immediate Medical Attention.
Masaki Y; Ueda Y; Yanagisawa H; Arita K; Sakai T; Yamada K; Mizuta S; Fukushima T; Takai K; Aoki S; Kawabata H
Intern Med; 2023 Jan; 62(1):27-32. PubMed ID: 35598998
[TBL] [Abstract][Full Text] [Related]
25. Aggressive TAFRO syndrome with reversible cardiomyopathy successfully treated with combination chemotherapy.
Yasuda S; Tanaka K; Ichikawa A; Watanabe K; Uchida E; Yamamoto M; Yamamoto K; Mizuchi D; Miura O; Fukuda T
Int J Hematol; 2016 Oct; 104(4):512-8. PubMed ID: 27245076
[TBL] [Abstract][Full Text] [Related]
26. A case of TAFRO syndrome, a variant of multicentric Castleman's disease, successfully treated with corticosteroid and cyclosporine A.
Takasawa N; Sekiguchi Y; Takahashi T; Muryoi A; Satoh J; Sasaki T
Mod Rheumatol; 2019 Jan; 29(1):198-202. PubMed ID: 27413814
[TBL] [Abstract][Full Text] [Related]
27. Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: A pediatric case series.
Lust H; Gong S; Remiker A; Rossoff J
Pediatr Blood Cancer; 2021 Oct; 68(10):e29261. PubMed ID: 34302703
[TBL] [Abstract][Full Text] [Related]
28. Optimal treatments for TAFRO syndrome: a retrospective surveillance study in Japan.
Fujimoto S; Kawabata H; Sakai T; Yanagisawa H; Nishikori M; Nara K; Ohara S; Tsukamoto N; Kurose N; Yamada S; Takai K; Aoki S; Masaki Y
Int J Hematol; 2021 Jan; 113(1):73-80. PubMed ID: 32970275
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease.
Iwaki N; Fajgenbaum DC; Nabel CS; Gion Y; Kondo E; Kawano M; Masunari T; Yoshida I; Moro H; Nikkuni K; Takai K; Matsue K; Kurosawa M; Hagihara M; Saito A; Okamoto M; Yokota K; Hiraiwa S; Nakamura N; Nakao S; Yoshino T; Sato Y
Am J Hematol; 2016 Feb; 91(2):220-6. PubMed ID: 26805758
[TBL] [Abstract][Full Text] [Related]
30. Stepwise Treatment for TAFRO Syndrome.
Ide M; Yokoyama T; Ishikawa M; Kojima K
J Med Cases; 2023 Nov; 14(11):369-377. PubMed ID: 38029058
[TBL] [Abstract][Full Text] [Related]
31. An extranodal histopathological analysis of idiopathic multicentric Castleman disease with and without TAFRO syndrome.
Kurose N; Mizutani KI; Kumagai M; Shioya A; Guo X; Nakada S; Fujimoto S; Kawabata H; Masaki Y; Takai K; Aoki S; Kojima M; Nakamura S; Kida M; Yamada S
Pathol Res Pract; 2019 Mar; 215(3):410-413. PubMed ID: 30642741
[TBL] [Abstract][Full Text] [Related]
32. Tocilizumab for the treatment of TAFRO syndrome: a systematic literature review.
Akiyama M; Kaneko Y; Takeuchi T
Ann Hematol; 2020 Nov; 99(11):2463-2475. PubMed ID: 32964342
[TBL] [Abstract][Full Text] [Related]
33. [A report of six TAFRO syndrome: clinical characteristics, diagnosis and treatment analysis].
Wu CB; Zhang HY; Shao SH; Dou LW; Zhou QY; Liu Y; Gao WB; Zhu JH
Zhonghua Yi Xue Za Zhi; 2020 Mar; 100(8):624-628. PubMed ID: 32164119
[No Abstract] [Full Text] [Related]
34. Intracranial Hemorrhage in a Patient with TAFRO Syndrome Treated with Cyclosporine A and Rituximab.
Akagi Y; Kato T; Yamashita Y; Hosoi H; Murata S; Yamamoto S; Warigaya K; Nakao T; Murata S; Sonoki T; Tamura S
Medicina (Kaunas); 2021 Sep; 57(9):. PubMed ID: 34577894
[TBL] [Abstract][Full Text] [Related]
35. Bone marrow findings of idiopathic Multicentric Castleman disease: A histopathologic analysis and systematic literature review.
Belyaeva E; Rubenstein A; Pierson SK; Dalldorf D; Frank D; Lim MS; Fajgenbaum DC
Hematol Oncol; 2022 Apr; 40(2):191-201. PubMed ID: 35104370
[TBL] [Abstract][Full Text] [Related]
36. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
Fajgenbaum DC
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):318-325. PubMed ID: 30504327
[TBL] [Abstract][Full Text] [Related]
37. Siltuximab Monotherapy in Tafro Syndrome: A Case Report and Review of the Literature.
Cordero L; Aguilar-Rodríguez F; Sandino J; Alonso M; Gutiérrez E
J Nephrol; 2023 May; 36(4):1181-1185. PubMed ID: 36652167
[TBL] [Abstract][Full Text] [Related]
38. [Clinical Anslysis of TAFRO Syndrome].
Liu F; Wei XF; Feng YF; Fu Y; Chen QL; Chen Y; Zhang QK
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1872-1877. PubMed ID: 38071075
[TBL] [Abstract][Full Text] [Related]
39. The experience of diagnosis and treatment for TAFRO syndrome.
Wu X; Zhang X; Qian S; Shi C; Li X; Feng X; Zhu L; Ge J; Li Z; Zhang M
Ann Hematol; 2023 Dec; 102(12):3515-3520. PubMed ID: 37713125
[TBL] [Abstract][Full Text] [Related]
40. Unicentric Castleman disease relapsed after rituximab-CHOP chemotherapy or radiation therapy in an adolescent.
Baek HJ; Kook H; Han DK; Shin MG; Kim HS; Hwang TJ
J Pediatr Hematol Oncol; 2012 Jul; 34(5):e206-8. PubMed ID: 22258344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
